Abstract

Allergen immunotherapy (AIT) has the exclusive ability to modify the natural history of allergy and to maintain its clinical efficacy also after stopping the treatment. This occurs because of the AIT mechanism of action, mainly consisting in a specific induction of tolerance to the causative allergen. Such tolerance takes place as a result of a complex interaction of innate and adaptive immunity processes, that involve inflammatory cells, cytokines and chemokines. The first response to allergens is provided by the antigen-presenting cells, and particularly by dendritic cells (Dcs) that, following activation, acquire chemokine receptors (CCRs), useful for migration to lymphoid organs, where adaptive immune response is induced. DCs act by presenting the antigen(s) to effectors T cells (T helper CD4 + and T suppressor CD8 +) derived from naïve T cells. The development of different cell subtypes from naïve T cells (Th0) may follow various pathways and depends on both individual genetic background (atopic/non atopic) and environmental factors. The T cell response in atopic subjects is influenced by the Th2 polarization promoting the production of cytokines such as IL-4 and IL- 5. On the contrary, the expression of CD80 may determine a Th1 cytokines production, and ICOS-L supports the Tregulatory cells activation that significantly reduce allergic inflammation. The suppressive effect of Treg is due to the expression of high level of the transcription factor Foxp3 on their surface, to the production of IL-10 and TGF-ß and to the expression of membrane molecules as CTL-4 PD-1 and BTLA. Recent advances highlighted a role also for Th9 and Th17 lymphocytes. Such immunologic modification leads to the long noted events in studies on mechanisms of action, such as the decrease of specific IgE and the increase of specific IgG1 and IgG4, and ultimately on the inhibition of inflammatory cells such as mast cells, basophils and eosinophils and on the control of clinical symptoms.

Highlights

  • One hundred years ago Noon reported the therapeutic efficacy of treatment with natural allergens for people suffering from respiratory allergy

  • The suppressive effect of Treg is due to the expression of high level of the transcription factor Foxp3 on their surface, to the production of Il-10 and TGF-ß and to the expression of membrane molecules as CTL-4 PD-1 and BTLA [33]

  • A recent study on a cohort of patients suffering from asthma and/or rhinoconjunctivitis due to sensitization to ragweed pollen treated with SLIT, demonstrated that this treatment is able to act on the different phases of the immune response: 1) by reducing the expression of costimulatory CD80 and CD86, on APCs and on monocytes and B lymphocytes; 2) by downregulating APC functions through an increase of the expression of programmed cell death ligand (PD-L1), that leads to IL-10 production; 3) by inducing IL-10 production by Treg cells, whereas it inhibits IL-4 producing cells; 4) by inducing a significant IgG4 increase [52]

Read more

Summary

Introduction

One hundred years ago Noon reported the therapeutic efficacy of treatment with natural allergens for people suffering from respiratory allergy. The first step of specific immunity, initiated by DCs, is the production of cytokines (IL-12, IL-10 and IFN-) promoting T regulatory cells activation and Th1 pattern of response.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call